This site requires flash 8 You currently do not have the necessary Macromedia Flash plug-in to view this page
Click here to download the Macromedia Flash plug-in
Trimipramine Maleate is an oral tertiary amine tricyclic antidepressant (TCA). Trimipramine Maleate was first synthesized in the 1950s during experiments designed to combine the effects of imipramine, an antidepressant, and levomepromazine, a phenothiazine. Although this drug is considered one of the most sedating TCAs, its anticholinergic effects are less pronounced than those which occur with amitriptyline. Like most other tricyclics, Trimipramine Maleate is FDA approved to treat depression. TCAs were a favored antidepressant treatment option for almost three decades until the introduction of the selective serotonin reuptake inhibitor (SSRI) class of antidepressants in 1988.
Trimipramine Maleate’s innovator is Odyssey Pharms and appears world-wide under the brand name Surmontil.
The precise mechanism of action of tricyclic antidepressants is not fully understood. In general, it is believed that tricyclics interfere with the reuptake of norepinephrine and serotonin at the presynaptic neuronal membrane. Serotonin and norepinephrine are thought to be involved in the regulation of mood, appetite, attentiveness, sleep, and other brain functions. Because mood elevation secondary to antidepressant therapy occurs only in depressed individuals and may require 2 to 3 weeks of therapy, a more recent theory has emerged to explain the mood-altering properties of antidepressants, which involves the eventual down-regulation of β-adrenoceptors. Interestingly, animal studies indicate that Trimipramine Maleate does not appear to have a significant effect on the reuptake of serotonin or norepinephrine, nor does it result in the down-regulation of β-adrenoceptors. Postsynaptic sensitization to serotonin has been postulated as one possible antidepressant mechanism of Trimipramine Maleate. Trimipramine Maleate also has D2-receptor antagonist properties, with an affinity for the D2 receptor which is similar to molindone.
The mechanisms responsible for the adverse events due to Trimipramine Maleate are varied. Unlike many psychotropic agents, Trimipramine Maleate does not suppress REM sleep. Sleep latency is decreased, REM sleep latency is increased, and time spent asleep is increased in depressed individuals receiving Trimipramine Maleate. Monoamine oxidase is not inhibited by tricyclic antidepressants.
Trimipramine Maleate appears in the following formulation and dosage: Capsules: 25 mg, 50 mg and 100 mg
General data on Trimipramine Maleate Active Pharmaceutical Ingredient
CAS Registry: 521-78-8 ATC: N06AA06 Molecular Formula: C20H26N2, C4H4O4 Molecular Weight: 410.5 Pharmacopoeias: In Eur.
Ph. Eur. 5.5: Trimipramine Maleate is a white or almost white crystalline powder. Trimipramine Maleate is slightly soluble in water and in alcohol.
TAPI's Trimipramine Maleate Active Pharmaceutical Ingredient is produced in Abic Limited in Netanya, Israel.
Trimipramine Maleate is produced by TAPI by Organic synthesis and considered to be medium volume Active Pharmaceutical Ingredient.
2008 Available DMF: U.S. DMF, EU CTD and CEP.
TAPI provide full service on Trimipramine Maleate and other APIs in our portfolio. Our local sales offices provide full information on our product, regulatory compliance and documentation on Trimipramine Maleate. Contact us today for further inquiries and samples and kilograms availability information for TAPI's Trimipramine Maleate.
Product exploitation, including development, sales and offer for sale are performed where permissible by patent law. This presentation is not and should not constitute an offer for sale in territories where it is not permitted by law. In USA Products that Currently on Patent are available for R&D Use in Accordance with 35 USC §271 (e) (1).
*TAPI stands for Teva's Active Pharmaceutical Ingredients
